Increase in newly reported COVID-19 infections is cause for concern 27% more new COVID-19 infections were reported last week than in the week before that.
Possible start of COVID-19 vaccination in early January If all goes well, the first people in the Netherlands will be vaccinated against COVID-19 in early January. The logistics operation aims to start vaccination in the week of 4 January 2021.
Only minor decrease in number of newly reported COVID-19 infections Last week there was a slight decrease in the number of newly reported COVID-19 infections: 33,949 newly reported infections in the past week compared to 36,931 newly reported infections in the week
COVID-19 consequences impact vulnerable groups more in the long term The effects of the corona crisis have a greater impact on vulnerable groups in society, such as lower-educated adults, young people, the elderly and people with underlying health problems.
Compliance with coronavirus measures has improved Autumn 2020 saw a strong surge in the number of people who tested positive for COVID-19.
Update on RIVM report “Silicone breast implants in the Netherlands”, State of Affairs October 2017 In June 2016, RIVM published the results of a study on breast implants in the Netherlands.
RIVM to contribute to new Horizon2020 project on oceans and human health across Europe A new EU Horizon2020 project Seas, Oceans and Public Health in Europe (SOPHIE) will explore the complex interplay between the health of the marine environment and that of humans.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Survey health complaints of women with a silicone breast implant This report provides a broad overview of the health complaints experienced by women with silicone breast implants in the Netherlands.
Efficiency and transparency of clinical drug trials must improve The efficiency and transparency of clinical drug trials in the Netherlands must improve. That concludes Sander van den Bogert in his PhD thesis ‘Trials & Tribulations.